Very risky_老虎社区_美港股上老虎

2021-04-09

Very risky

How AstraZeneca's latest vaccine troubles could slow the global recovery<blockquote>阿斯利康最新的疫苗问题如何减缓全球复苏</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":348576426,"tweetId":"348576426","gmtCreate":1617946816865,"gmtModify":1634295582283,"author":{"id":3579141850161287,"idStr":"3579141850161287","authorId":3579141850161287,"authorIdStr":"3579141850161287","name":"GoaOn","avatar":"https://static.tigerbbs.com/c41bfb0b74d5d9d2f6a9ec08f3a8cb42","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Very risky</body></html>","htmlText":"<html><head></head><body>Very risky</body></html>","text":"Very risky","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/348576426","repostId":1143257559,"repostType":4,"repost":{"id":"1143257559","kind":"news","pubTimestamp":1617945822,"share":"https://www.laohu8.com/m/news/1143257559?lang=zh_CN&edition=full","pubTime":"2021-04-09 13:23","market":"uk","language":"en","title":"How AstraZeneca's latest vaccine troubles could slow the global recovery<blockquote>阿斯利康最新的疫苗问题如何减缓全球复苏</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1143257559","media":"cnn","summary":"London (CNN Business) AstraZeneca's vaccine is key to ending the global economic slump caused by the","content":"London (CNN Business)&nbsp;AstraZeneca's vaccine is key to ending the global economic slump caused by the coronavirus. But a series of missteps by the drugmaker and new concerns over blood clots risk undermining public confidence in the shot and delaying the recovery.<blockquote>伦敦（CNN商业）阿斯利康的疫苗是结束冠状病毒引起的全球经济衰退的关键。但该制药商的一系列失误以及对血栓的新担忧可能会削弱公众对该疫苗的信心并推迟康复。</blockquote>European drug regulators said there was a possible link between the Oxford-AstraZeneca Covid-19 shot and rare blood clots on Wednesday, but stopped short of recommending its use be limited. UK authorities recommended that people under 30 take alternative vaccines.<blockquote>欧洲药品监管机构周三表示，牛津-阿斯利康Covid-19疫苗与罕见血栓之间可能存在联系，但没有建议限制其使用。英国当局建议30岁以下的人接种替代疫苗。</blockquote>It's the latest setback for AstraZeneca (AZN), which has faced criticism over its communication with the public and regulators, the design of its vaccine trials and severe production delays that have slowed the rollout of shots in Europe.<blockquote>这是阿斯利康（AZN）的最新挫折，该公司因其与公众和监管机构的沟通、疫苗试验的设计以及严重的生产延误而面临批评，这些延误减缓了疫苗在欧洲的推广。</blockquote>Authorities maintain that the benefits of the vaccine far outweigh the risks for most age groups. Yet shifting guidance and blood clot worries risk snarling distribution efforts in many countries. Germany suspended the use of the AstraZeneca vaccine last week in people under 60 years old, while Australia said Thursday it will not give it to people under the age of 50.<blockquote>当局坚持认为，对大多数年龄组来说，疫苗的好处远远超过风险。然而，指导方针的转变和血栓的担忧可能会扰乱许多国家的分销工作。德国上周暂停在60岁以下人群中使用阿斯利康疫苗，而澳大利亚周四表示不会给50岁以下人群接种。</blockquote>The safety questions could have even bigger implications for developing and middle-income countries, many of which are relying on the shot to unlock their economic comebacks because it's cheaper than other vaccines and can be stored more easily. Many are accessing it through Covax, a global vaccine-sharing program, which has secured more than half its supply from AstraZeneca as of March.<blockquote>安全问题可能会对发展中国家和中等收入国家产生更大的影响，其中许多国家依靠疫苗来实现经济复苏，因为它比其他疫苗更便宜，而且更容易储存。许多人通过全球疫苗共享计划Covax获得疫苗，截至3月份，该计划已从阿斯利康获得一半以上的供应。</blockquote>Overall, orders for an estimated 2.4 billion doses of AstraZeneca's vaccine have been confirmed, according to the Duke Global Health Innovation Center. That's roughly 28% of the global total.<blockquote>根据杜克全球健康创新中心的数据，总体而言，估计有24亿剂阿斯利康疫苗的订单已得到确认。这大约占全球总数的28%。</blockquote>\"There's a lot of uncertainty here,\" said Ben May, director of macro research at Oxford Economics. He said the AstraZeneca developments weren't enough to revise near-term growth forecasts, but that he would keep monitoring the situation closely.<blockquote>牛津经济研究院宏观研究主管本·梅表示：“这里存在很多不确定性。”他表示，阿斯利康的进展不足以修改近期增长预测，但他将继续密切关注局势。</blockquote>The World Health Organization said in a statement Wednesday that \"based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed.\"<blockquote>世界卫生组织周三在一份声明中表示，“根据目前的信息，疫苗与低血小板血栓的发生之间的因果关系被认为是合理的，但尚未得到证实。”</blockquote>AstraZeneca said that nearly 200 million people around the world have already received its vaccine, and that reviews by EU and UK regulators \"reaffirmed the vaccine offers a high-level of protection against all severities of Covid-19 and that these benefits continue to far outweigh the risks.\"<blockquote>阿斯利康表示，全球已有近2亿人接种了疫苗，欧盟和英国监管机构的审查“重申该疫苗可针对所有严重程度的Covid-19提供高水平的保护，并且这些益处继续远远超过风险。”</blockquote>A rough start<blockquote>艰难的开始</blockquote>AstraZeneca received emergency use authorization from the United Kingdom in late December and the European Union one month later. Because the vaccine was less expensive and could be stored at higher temperatures than ones developed by Pfizer (PFE) and Moderna (MRNA), it was heralded as a breakthrough, particularly for less affluent countries that lack sophisticated logistics networks.<blockquote>阿斯利康于12月下旬获得英国的紧急使用授权，一个月后获得欧盟的紧急使用授权。由于该疫苗比辉瑞(PFE)和Moderna(MRNA)开发的疫苗更便宜，并且可以在更高的温度下储存，因此被誉为一项突破，特别是对于缺乏复杂物流网络的不太富裕的国家。</blockquote>The company also generated lots of goodwill by pledging to supply its vaccine at no profit during the pandemic, and by partnering with the Serum Institute of India, which agreed to produce more than 1 billion doses for low and middle-income countries. AstraZeneca has already provided over 30 million doses to more than 58 countries through Covax.<blockquote>该公司还通过承诺在疫情期间无偿供应疫苗，以及与印度血清研究所合作，产生了大量善意，印度血清研究所同意为中低收入国家生产超过10亿剂疫苗。阿斯利康已通过Covax向超过58个国家提供了超过3000万剂疫苗。</blockquote>However, a series of missteps generated a string of bad headlines for the Anglo-Swedish drugmaker.<blockquote>然而，一系列失误给这家英瑞制药商带来了一系列糟糕的头条新闻。</blockquote>The first issue cropped up in November, when the company faced questions about data from large-scale trials. Volunteers received different doses due to a manufacturing error, creating confusion about its actual effectiveness.<blockquote>第一个问题出现在11月份，当时该公司面临有关大规模试验数据的质疑。由于制造错误，志愿者接受了不同的剂量，造成了对其实际有效性的混淆。</blockquote>AstraZeneca did not mention that a mistake caused the dosing discrepancy in its initial announcement, generating concerns about a lack of transparency.<blockquote>阿斯利康在最初的公告中没有提到错误导致了剂量差异，这引发了人们对缺乏透明度的担忧。</blockquote>\"I hate to criticize fellow academics, or anyone for that matter, but releasing information like this is like asking us to try and read the tea leaves,\" Dr. Saad Omer, a vaccine specialist at the Yale School of Medicine, said at the time.<blockquote>耶鲁大学医学院疫苗专家萨阿德·奥马尔博士当时表示：“我讨厌批评其他学者或任何人，但发布这样的信息就像要求我们尝试阅读茶叶一样。”。</blockquote>More stumbles followed. Germany's vaccine commission said in January that AstraZeneca's shots shouldn't be given to people older than 65, citing insufficient data for the age group. France also initially limited AstraZeneca vaccines to those under 65. Both countries changed course last month.<blockquote>更多的失误接踵而至。德国疫苗委员会一月份表示，阿斯利康疫苗不应给65岁以上的人注射，理由是该年龄组的数据不足。法国最初也将阿斯利康疫苗限制在65岁以下的人群。两国上个月都改变了方针。</blockquote>Jeffrey Lazarus, head of the health systems research group at the Barcelona Institute for Global Health, previously told CNN Business this was an \"easily avoidable\" issue tied to trial design.<blockquote>巴塞罗那全球健康研究所卫生系统研究小组负责人杰弗里·拉扎勒斯(Jeffrey Lazarus)此前告诉CNN Business，这是一个与试验设计相关的“容易避免”的问题。</blockquote>Had the vaccine rollout been smooth, such stumbles may have been forgotten. But continued shortfalls in supply of the AstraZeneca shots in Europe, which is now mired in a third wave of coronavirus infections, have triggered huge political blowback in the bloc. Leaders have imposed restrictions on vaccine exports.<blockquote>如果疫苗的推广顺利，这样的失误可能会被遗忘。但欧洲阿斯利康疫苗供应持续短缺，目前正陷入第三波冠状病毒感染，在欧盟引发了巨大的政治反弹。领导人对疫苗出口实施了限制。</blockquote>\"If we had received the 100% of AstraZeneca's vaccines that were contracted to us, the European Union would be at the same level today as Great Britain in terms of vaccines,\" European Commissioner Thierry Breton said in a recent interview with Le Parisien newspaper. \"So I can say that the pocket of turbulence we have experienced is solely due to AstraZeneca's failure to deliver.\"<blockquote>欧盟专员蒂埃里·布雷顿(Thierry Breton)最近在接受《巴黎人报》采访时表示：“如果我们100%收到了阿斯利康合同给我们的疫苗，欧盟今天在疫苗方面将与英国处于同一水平。”“所以我可以说，我们所经历的动荡完全是由于阿斯利康未能交付。”</blockquote>AstraZeneca's future role<blockquote>阿斯利康未来的角色</blockquote>The company also ran afoul of US regulators last month when it submitted trial data from the country. The US National Institute of Allergy and Infectious Diseases expressed concerns that the efficacy information submitted was \"outdated.\" AstraZeneca quickly sent in revised data, but Dr. Anthony Fauci, the agency's director, called it \"an unforced error.\"<blockquote>上个月，该公司在提交美国试验数据时也与美国监管机构发生了冲突。美国国家过敏症和传染病研究所对提交的疗效信息“过时”表示担忧。阿斯利康很快发送了修改后的数据，但该机构主任安东尼·福奇博士称其为“非受迫性错误”。</blockquote>Now, as fears about rare blood clots force governments around the world to reassess the risk-benefit analysis of providing shots to all age groups, the United States has indicated it does not need AstraZeneca's doses.<blockquote>现在，由于对罕见血栓的担忧迫使世界各国政府重新评估向所有年龄组提供疫苗的风险效益分析，美国已表示不需要阿斯利康的剂量。</blockquote>\"We have enough very good vaccines,\" Fauci, who also serves as chief medical adviser to President Joe Biden, told CNN on Wednesday.<blockquote>“我们有足够多的非常好的疫苗，”同时担任总统乔·拜登首席医疗顾问的福奇周三告诉美国有线电视新闻网。</blockquote>Not all countries will have that luxury, however. India, for example, is leaning heavily on AstraZeneca's shot as it tries to fight back against an alarming spike in cases.<blockquote>然而，并非所有国家都有这种奢侈。例如，印度在试图反击病例激增时严重依赖阿斯利康的疫苗。</blockquote>Lazarus said Thursday that if wealthier nations decide they want to reduce their reliance on AstraZeneca, he hopes shots can be sent to other nations in need, since the data still indicates it's safe and effective.<blockquote>拉扎勒斯周四表示，如果富裕国家决定减少对阿斯利康的依赖，他希望可以将疫苗发送到其他有需要的国家，因为数据仍然表明它是安全有效的。</blockquote>\"There are plenty of other countries that don't have other options because of the logistics ... and because of the cost,\" he said.<blockquote>“还有很多其他国家因为物流……和成本而没有其他选择，”他说。</blockquote>He does worry, however, that all the bad publicity could affect people's willingness to accept an AstraZeneca vaccine when it becomes available.<blockquote>然而，他确实担心所有的负面宣传可能会影响人们在阿斯利康疫苗上市时接受它的意愿。</blockquote>\"This is definitely going to impact the reputation of the AstraZeneca vaccine,\" Lazarus said. \"[It] will lead to lower uptake.\"<blockquote>“这肯定会影响阿斯利康疫苗的声誉，”拉扎勒斯说。“[它]会导致吸收率降低。”</blockquote>That could be bad news for the global economic recovery. This week, the International Monetary Fund upgraded its forecast for global growth this year to 6%. But that estimate depends in part on the pace of the vaccine rollout.<blockquote>这对全球经济复苏来说可能是个坏消息。本周，国际货币基金组织将今年全球增长预期上调至6%。但这一估计部分取决于疫苗推出的速度。</blockquote>\"Anything that might effectively reduce vaccine availability is obviously not good news,\" said May of Oxford Economics.<blockquote>牛津经济研究院的梅表示：“任何可能有效减少疫苗供应的事情显然都不是好消息。”</blockquote>The vaccine \"is still usable for the most vulnerable sections of the population,\" he noted. But coupled with supply shortages, new restrictions could complicate the recovery in countries where AstraZeneca's vaccine is central to pandemic exit strategies, May said.<blockquote>他指出，该疫苗“仍然可用于最脆弱的人群”。但梅表示，再加上供应短缺，新的限制措施可能会使阿斯利康疫苗是大流行退出战略核心的国家的复苏复杂化。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How AstraZeneca's latest vaccine troubles could slow the global recovery<blockquote>阿斯利康最新的疫苗问题如何减缓全球复苏</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow AstraZeneca's latest vaccine troubles could slow the global recovery<blockquote>阿斯利康最新的疫苗问题如何减缓全球复苏</blockquote>\n</h2>\n<h4 class=\"meta\">\n\ncnn2021-04-09 13:23\n\n</h4>\n</header>\n<article>\nLondon (CNN Business)&nbsp;AstraZeneca's vaccine is key to ending the global economic slump caused by the coronavirus. But a series of missteps by the drugmaker and new concerns over blood clots risk undermining public confidence in the shot and delaying the recovery.<blockquote>伦敦（CNN商业）阿斯利康的疫苗是结束冠状病毒引起的全球经济衰退的关键。但该制药商的一系列失误以及对血栓的新担忧可能会削弱公众对该疫苗的信心并推迟康复。</blockquote>European drug regulators said there was a possible link between the Oxford-AstraZeneca Covid-19 shot and rare blood clots on Wednesday, but stopped short of recommending its use be limited. UK authorities recommended that people under 30 take alternative vaccines.<blockquote>欧洲药品监管机构周三表示，牛津-阿斯利康Covid-19疫苗与罕见血栓之间可能存在联系，但没有建议限制其使用。英国当局建议30岁以下的人接种替代疫苗。</blockquote>It's the latest setback for AstraZeneca (AZN), which has faced criticism over its communication with the public and regulators, the design of its vaccine trials and severe production delays that have slowed the rollout of shots in Europe.<blockquote>这是阿斯利康（AZN）的最新挫折，该公司因其与公众和监管机构的沟通、疫苗试验的设计以及严重的生产延误而面临批评，这些延误减缓了疫苗在欧洲的推广。</blockquote>Authorities maintain that the benefits of the vaccine far outweigh the risks for most age groups. Yet shifting guidance and blood clot worries risk snarling distribution efforts in many countries. Germany suspended the use of the AstraZeneca vaccine last week in people under 60 years old, while Australia said Thursday it will not give it to people under the age of 50.<blockquote>当局坚持认为，对大多数年龄组来说，疫苗的好处远远超过风险。然而，指导方针的转变和血栓的担忧可能会扰乱许多国家的分销工作。德国上周暂停在60岁以下人群中使用阿斯利康疫苗，而澳大利亚周四表示不会给50岁以下人群接种。</blockquote>The safety questions could have even bigger implications for developing and middle-income countries, many of which are relying on the shot to unlock their economic comebacks because it's cheaper than other vaccines and can be stored more easily. Many are accessing it through Covax, a global vaccine-sharing program, which has secured more than half its supply from AstraZeneca as of March.<blockquote>安全问题可能会对发展中国家和中等收入国家产生更大的影响，其中许多国家依靠疫苗来实现经济复苏，因为它比其他疫苗更便宜，而且更容易储存。许多人通过全球疫苗共享计划Covax获得疫苗，截至3月份，该计划已从阿斯利康获得一半以上的供应。</blockquote>Overall, orders for an estimated 2.4 billion doses of AstraZeneca's vaccine have been confirmed, according to the Duke Global Health Innovation Center. That's roughly 28% of the global total.<blockquote>根据杜克全球健康创新中心的数据，总体而言，估计有24亿剂阿斯利康疫苗的订单已得到确认。这大约占全球总数的28%。</blockquote>\"There's a lot of uncertainty here,\" said Ben May, director of macro research at Oxford Economics. He said the AstraZeneca developments weren't enough to revise near-term growth forecasts, but that he would keep monitoring the situation closely.<blockquote>牛津经济研究院宏观研究主管本·梅表示：“这里存在很多不确定性。”他表示，阿斯利康的进展不足以修改近期增长预测，但他将继续密切关注局势。</blockquote>The World Health Organization said in a statement Wednesday that \"based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed.\"<blockquote>世界卫生组织周三在一份声明中表示，“根据目前的信息，疫苗与低血小板血栓的发生之间的因果关系被认为是合理的，但尚未得到证实。”</blockquote>AstraZeneca said that nearly 200 million people around the world have already received its vaccine, and that reviews by EU and UK regulators \"reaffirmed the vaccine offers a high-level of protection against all severities of Covid-19 and that these benefits continue to far outweigh the risks.\"<blockquote>阿斯利康表示，全球已有近2亿人接种了疫苗，欧盟和英国监管机构的审查“重申该疫苗可针对所有严重程度的Covid-19提供高水平的保护，并且这些益处继续远远超过风险。”</blockquote>A rough start<blockquote>艰难的开始</blockquote>AstraZeneca received emergency use authorization from the United Kingdom in late December and the European Union one month later. Because the vaccine was less expensive and could be stored at higher temperatures than ones developed by Pfizer (PFE) and Moderna (MRNA), it was heralded as a breakthrough, particularly for less affluent countries that lack sophisticated logistics networks.<blockquote>阿斯利康于12月下旬获得英国的紧急使用授权，一个月后获得欧盟的紧急使用授权。由于该疫苗比辉瑞(PFE)和Moderna(MRNA)开发的疫苗更便宜，并且可以在更高的温度下储存，因此被誉为一项突破，特别是对于缺乏复杂物流网络的不太富裕的国家。</blockquote>The company also generated lots of goodwill by pledging to supply its vaccine at no profit during the pandemic, and by partnering with the Serum Institute of India, which agreed to produce more than 1 billion doses for low and middle-income countries. AstraZeneca has already provided over 30 million doses to more than 58 countries through Covax.<blockquote>该公司还通过承诺在疫情期间无偿供应疫苗，以及与印度血清研究所合作，产生了大量善意，印度血清研究所同意为中低收入国家生产超过10亿剂疫苗。阿斯利康已通过Covax向超过58个国家提供了超过3000万剂疫苗。</blockquote>However, a series of missteps generated a string of bad headlines for the Anglo-Swedish drugmaker.<blockquote>然而，一系列失误给这家英瑞制药商带来了一系列糟糕的头条新闻。</blockquote>The first issue cropped up in November, when the company faced questions about data from large-scale trials. Volunteers received different doses due to a manufacturing error, creating confusion about its actual effectiveness.<blockquote>第一个问题出现在11月份，当时该公司面临有关大规模试验数据的质疑。由于制造错误，志愿者接受了不同的剂量，造成了对其实际有效性的混淆。</blockquote>AstraZeneca did not mention that a mistake caused the dosing discrepancy in its initial announcement, generating concerns about a lack of transparency.<blockquote>阿斯利康在最初的公告中没有提到错误导致了剂量差异，这引发了人们对缺乏透明度的担忧。</blockquote>\"I hate to criticize fellow academics, or anyone for that matter, but releasing information like this is like asking us to try and read the tea leaves,\" Dr. Saad Omer, a vaccine specialist at the Yale School of Medicine, said at the time.<blockquote>耶鲁大学医学院疫苗专家萨阿德·奥马尔博士当时表示：“我讨厌批评其他学者或任何人，但发布这样的信息就像要求我们尝试阅读茶叶一样。”。</blockquote>More stumbles followed. Germany's vaccine commission said in January that AstraZeneca's shots shouldn't be given to people older than 65, citing insufficient data for the age group. France also initially limited AstraZeneca vaccines to those under 65. Both countries changed course last month.<blockquote>更多的失误接踵而至。德国疫苗委员会一月份表示，阿斯利康疫苗不应给65岁以上的人注射，理由是该年龄组的数据不足。法国最初也将阿斯利康疫苗限制在65岁以下的人群。两国上个月都改变了方针。</blockquote>Jeffrey Lazarus, head of the health systems research group at the Barcelona Institute for Global Health, previously told CNN Business this was an \"easily avoidable\" issue tied to trial design.<blockquote>巴塞罗那全球健康研究所卫生系统研究小组负责人杰弗里·拉扎勒斯(Jeffrey Lazarus)此前告诉CNN Business，这是一个与试验设计相关的“容易避免”的问题。</blockquote>Had the vaccine rollout been smooth, such stumbles may have been forgotten. But continued shortfalls in supply of the AstraZeneca shots in Europe, which is now mired in a third wave of coronavirus infections, have triggered huge political blowback in the bloc. Leaders have imposed restrictions on vaccine exports.<blockquote>如果疫苗的推广顺利，这样的失误可能会被遗忘。但欧洲阿斯利康疫苗供应持续短缺，目前正陷入第三波冠状病毒感染，在欧盟引发了巨大的政治反弹。领导人对疫苗出口实施了限制。</blockquote>\"If we had received the 100% of AstraZeneca's vaccines that were contracted to us, the European Union would be at the same level today as Great Britain in terms of vaccines,\" European Commissioner Thierry Breton said in a recent interview with Le Parisien newspaper. \"So I can say that the pocket of turbulence we have experienced is solely due to AstraZeneca's failure to deliver.\"<blockquote>欧盟专员蒂埃里·布雷顿(Thierry Breton)最近在接受《巴黎人报》采访时表示：“如果我们100%收到了阿斯利康合同给我们的疫苗，欧盟今天在疫苗方面将与英国处于同一水平。”“所以我可以说，我们所经历的动荡完全是由于阿斯利康未能交付。”</blockquote>AstraZeneca's future role<blockquote>阿斯利康未来的角色</blockquote>The company also ran afoul of US regulators last month when it submitted trial data from the country. The US National Institute of Allergy and Infectious Diseases expressed concerns that the efficacy information submitted was \"outdated.\" AstraZeneca quickly sent in revised data, but Dr. Anthony Fauci, the agency's director, called it \"an unforced error.\"<blockquote>上个月，该公司在提交美国试验数据时也与美国监管机构发生了冲突。美国国家过敏症和传染病研究所对提交的疗效信息“过时”表示担忧。阿斯利康很快发送了修改后的数据，但该机构主任安东尼·福奇博士称其为“非受迫性错误”。</blockquote>Now, as fears about rare blood clots force governments around the world to reassess the risk-benefit analysis of providing shots to all age groups, the United States has indicated it does not need AstraZeneca's doses.<blockquote>现在，由于对罕见血栓的担忧迫使世界各国政府重新评估向所有年龄组提供疫苗的风险效益分析，美国已表示不需要阿斯利康的剂量。</blockquote>\"We have enough very good vaccines,\" Fauci, who also serves as chief medical adviser to President Joe Biden, told CNN on Wednesday.<blockquote>“我们有足够多的非常好的疫苗，”同时担任总统乔·拜登首席医疗顾问的福奇周三告诉美国有线电视新闻网。</blockquote>Not all countries will have that luxury, however. India, for example, is leaning heavily on AstraZeneca's shot as it tries to fight back against an alarming spike in cases.<blockquote>然而，并非所有国家都有这种奢侈。例如，印度在试图反击病例激增时严重依赖阿斯利康的疫苗。</blockquote>Lazarus said Thursday that if wealthier nations decide they want to reduce their reliance on AstraZeneca, he hopes shots can be sent to other nations in need, since the data still indicates it's safe and effective.<blockquote>拉扎勒斯周四表示，如果富裕国家决定减少对阿斯利康的依赖，他希望可以将疫苗发送到其他有需要的国家，因为数据仍然表明它是安全有效的。</blockquote>\"There are plenty of other countries that don't have other options because of the logistics ... and because of the cost,\" he said.<blockquote>“还有很多其他国家因为物流……和成本而没有其他选择，”他说。</blockquote>He does worry, however, that all the bad publicity could affect people's willingness to accept an AstraZeneca vaccine when it becomes available.<blockquote>然而，他确实担心所有的负面宣传可能会影响人们在阿斯利康疫苗上市时接受它的意愿。</blockquote>\"This is definitely going to impact the reputation of the AstraZeneca vaccine,\" Lazarus said. \"[It] will lead to lower uptake.\"<blockquote>“这肯定会影响阿斯利康疫苗的声誉，”拉扎勒斯说。“[它]会导致吸收率降低。”</blockquote>That could be bad news for the global economic recovery. This week, the International Monetary Fund upgraded its forecast for global growth this year to 6%. But that estimate depends in part on the pace of the vaccine rollout.<blockquote>这对全球经济复苏来说可能是个坏消息。本周，国际货币基金组织将今年全球增长预期上调至6%。但这一估计部分取决于疫苗推出的速度。</blockquote>\"Anything that might effectively reduce vaccine availability is obviously not good news,\" said May of Oxford Economics.<blockquote>牛津经济研究院的梅表示：“任何可能有效减少疫苗供应的事情显然都不是好消息。”</blockquote>The vaccine \"is still usable for the most vulnerable sections of the population,\" he noted. But coupled with supply shortages, new restrictions could complicate the recovery in countries where AstraZeneca's vaccine is central to pandemic exit strategies, May said.<blockquote>他指出，该疫苗“仍然可用于最脆弱的人群”。但梅表示，再加上供应短缺，新的限制措施可能会使阿斯利康疫苗是大流行退出战略核心的国家的复苏复杂化。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://edition.cnn.com/2021/04/08/business/astrazeneca-vaccine-corporate-problems/index.html\">cnn</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","AZN.UK":"阿斯利康制药"},"source_url":"https://edition.cnn.com/2021/04/08/business/astrazeneca-vaccine-corporate-problems/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143257559","content_text":"London (CNN Business) AstraZeneca's vaccine is key to ending the global economic slump caused by the coronavirus. But a series of missteps by the drugmaker and new concerns over blood clots risk undermining public confidence in the shot and delaying the recovery.European drug regulators said there was a possible link between the Oxford-AstraZeneca Covid-19 shot and rare blood clots on Wednesday, but stopped short of recommending its use be limited. UK authorities recommended that people under 30 take alternative vaccines.It's the latest setback for AstraZeneca (AZN), which has faced criticism over its communication with the public and regulators, the design of its vaccine trials and severe production delays that have slowed the rollout of shots in Europe.Authorities maintain that the benefits of the vaccine far outweigh the risks for most age groups. Yet shifting guidance and blood clot worries risk snarling distribution efforts in many countries. Germany suspended the use of the AstraZeneca vaccine last week in people under 60 years old, while Australia said Thursday it will not give it to people under the age of 50.The safety questions could have even bigger implications for developing and middle-income countries, many of which are relying on the shot to unlock their economic comebacks because it's cheaper than other vaccines and can be stored more easily. Many are accessing it through Covax, a global vaccine-sharing program, which has secured more than half its supply from AstraZeneca as of March.Overall, orders for an estimated 2.4 billion doses of AstraZeneca's vaccine have been confirmed, according to the Duke Global Health Innovation Center. That's roughly 28% of the global total.\"There's a lot of uncertainty here,\" said Ben May, director of macro research at Oxford Economics. He said the AstraZeneca developments weren't enough to revise near-term growth forecasts, but that he would keep monitoring the situation closely.The World Health Organization said in a statement Wednesday that \"based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed.\"AstraZeneca said that nearly 200 million people around the world have already received its vaccine, and that reviews by EU and UK regulators \"reaffirmed the vaccine offers a high-level of protection against all severities of Covid-19 and that these benefits continue to far outweigh the risks.\"A rough startAstraZeneca received emergency use authorization from the United Kingdom in late December and the European Union one month later. Because the vaccine was less expensive and could be stored at higher temperatures than ones developed by Pfizer (PFE) and Moderna (MRNA), it was heralded as a breakthrough, particularly for less affluent countries that lack sophisticated logistics networks.The company also generated lots of goodwill by pledging to supply its vaccine at no profit during the pandemic, and by partnering with the Serum Institute of India, which agreed to produce more than 1 billion doses for low and middle-income countries. AstraZeneca has already provided over 30 million doses to more than 58 countries through Covax.However, a series of missteps generated a string of bad headlines for the Anglo-Swedish drugmaker.The first issue cropped up in November, when the company faced questions about data from large-scale trials. Volunteers received different doses due to a manufacturing error, creating confusion about its actual effectiveness.AstraZeneca did not mention that a mistake caused the dosing discrepancy in its initial announcement, generating concerns about a lack of transparency.\"I hate to criticize fellow academics, or anyone for that matter, but releasing information like this is like asking us to try and read the tea leaves,\" Dr. Saad Omer, a vaccine specialist at the Yale School of Medicine, said at the time.More stumbles followed. Germany's vaccine commission said in January that AstraZeneca's shots shouldn't be given to people older than 65, citing insufficient data for the age group. France also initially limited AstraZeneca vaccines to those under 65. Both countries changed course last month.Jeffrey Lazarus, head of the health systems research group at the Barcelona Institute for Global Health, previously told CNN Business this was an \"easily avoidable\" issue tied to trial design.Had the vaccine rollout been smooth, such stumbles may have been forgotten. But continued shortfalls in supply of the AstraZeneca shots in Europe, which is now mired in a third wave of coronavirus infections, have triggered huge political blowback in the bloc. Leaders have imposed restrictions on vaccine exports.\"If we had received the 100% of AstraZeneca's vaccines that were contracted to us, the European Union would be at the same level today as Great Britain in terms of vaccines,\" European Commissioner Thierry Breton said in a recent interview with Le Parisien newspaper. \"So I can say that the pocket of turbulence we have experienced is solely due to AstraZeneca's failure to deliver.\"AstraZeneca's future roleThe company also ran afoul of US regulators last month when it submitted trial data from the country. The US National Institute of Allergy and Infectious Diseases expressed concerns that the efficacy information submitted was \"outdated.\" AstraZeneca quickly sent in revised data, but Dr. Anthony Fauci, the agency's director, called it \"an unforced error.\"Now, as fears about rare blood clots force governments around the world to reassess the risk-benefit analysis of providing shots to all age groups, the United States has indicated it does not need AstraZeneca's doses.\"We have enough very good vaccines,\" Fauci, who also serves as chief medical adviser to President Joe Biden, told CNN on Wednesday.Not all countries will have that luxury, however. India, for example, is leaning heavily on AstraZeneca's shot as it tries to fight back against an alarming spike in cases.Lazarus said Thursday that if wealthier nations decide they want to reduce their reliance on AstraZeneca, he hopes shots can be sent to other nations in need, since the data still indicates it's safe and effective.\"There are plenty of other countries that don't have other options because of the logistics ... and because of the cost,\" he said.He does worry, however, that all the bad publicity could affect people's willingness to accept an AstraZeneca vaccine when it becomes available.\"This is definitely going to impact the reputation of the AstraZeneca vaccine,\" Lazarus said. \"[It] will lead to lower uptake.\"That could be bad news for the global economic recovery. This week, the International Monetary Fund upgraded its forecast for global growth this year to 6%. But that estimate depends in part on the pace of the vaccine rollout.\"Anything that might effectively reduce vaccine availability is obviously not good news,\" said May of Oxford Economics.The vaccine \"is still usable for the most vulnerable sections of the population,\" he noted. But coupled with supply shortages, new restrictions could complicate the recovery in countries where AstraZeneca's vaccine is central to pandemic exit strategies, May said.","news_type":1,"symbols_score_info":{"AZN":0.9,"AZN.UK":0.9}},"isVote":1,"tweetType":1,"viewCount":322,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":9,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/348576426"}